Clinical trial
A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy
NCT01093170 is registered in ClinicalTrials.gov with Mark Kleinman as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy
- Lead sponsor
- Mark Kleinman
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- March 31, 2011
- Completion date
- September 30, 2012
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.